NCT02223013View on ClinicalTrials.gov

Relative Bioavailability and Tolerability of Two New Different Extended Release Capsules of BIBV 308 SE, Versus a Solution of BIBV 308 SE in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

April 30, 1999

Primary Completion Date

May 31, 1999

Conditions
Healthy
Interventions
DRUG

BIBV 308 SE solution

DRUG

BIBV 308 SE capsule L

DRUG

BIBV 308 SE capsule S

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT02223013 - Relative Bioavailability and Tolerability of Two New Different Extended Release Capsules of BIBV 308 SE, Versus a Solution of BIBV 308 SE in Healthy Subjects | Biotech Hunter | Biotech Hunter